TOOKAD 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
IAIN/0020 
A.1 - Administrative change - Change in the name 
07/12/2022 
and/or address of the MAH 
amended 
on 
SmPC, 
Labelling and 
PL 
R/0019 
Renewal of the marketing authorisation. 
21/07/2022 
26/09/2022 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL 
the CHMP considered that the benefit-risk balance of 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202111 
padeliporfin 
IA/0018/G 
This was an application for a group of variations. 
14/02/2022 
n/a 
TOOKAD in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
II/0015 
Submission of the Clinical Study Report for Category 
10/02/2022 
21/06/2022 
Annex II 
The Clinical Study Report for Category 1 study CLIN1001 
1 study: Post-authorisation efficacy study (PAES) 
CLIN1001 PCM301FU5, A European Randomised 
Phase 3 Study to Assess the Efficacy and Safety of 
TOOKAD Soluble for Localised Prostate Cancer 
compared to Active Surveillance. The Annex II has 
been updated to remove reference to this study. The 
RMP version 8.0 is approved. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
PCM301FU5 has been submitted and the Annex II has been 
updated to remove reference to this study. 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202105 
padeliporfin 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202011 
padeliporfin 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
25/05/2021 
21/06/2022 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0011 
C.I.11.z - Introduction of, or change(s) to, the 
17/12/2020 
04/02/2021 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
26/11/2020 
n/a 
PRAC Recommendation - maintenance 
/202005 
padeliporfin 
IB/0008/G 
This was an application for a group of variations. 
08/09/2020 
n/a 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
IA/0010 
B.II.e.2.c - Change in the specification parameters 
07/09/2020 
n/a 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
specification parameter (e.g. deletion of an obsolete 
parameter) 
IB/0009 
B.II.b.3.z - Change in the manufacturing process of 
12/08/2020 
n/a 
the finished or intermediate product - Other variation 
IB/0007 
B.II.b.5.z - Change to in-process tests or limits 
12/08/2020 
n/a 
applied during the manufacture of the finished 
product - Other variation 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
/201911 
padeliporfin 
IAIN/0005 
A.5.a - Administrative change - Change in the name 
20/02/2020 
04/02/2021 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
28/11/2019 
n/a 
PRAC Recommendation - maintenance 
/201905 
padeliporfin 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
14/06/2019 
n/a 
PRAC Recommendation - maintenance 
/201811 
padeliporfin 
PSUSA/10654
Periodic Safety Update EU Single assessment - 
29/11/2018 
n/a 
PRAC Recommendation - maintenance 
/201805 
padeliporfin 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
